Trial · NCT03890120
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Blinded Treatment Phase (100.3 Weeks) | STARTED | Cilofexor 100 mg (Blinded Phase) | 278 | |
| Blinded Treatment Phase (100.3 Weeks) | STARTED | Placebo (Blinded Phase) | 141 | |
| Blinded Treatment Phase (100.3 Weeks) | STARTED | Cilofexor From Cilofexor 100 mg (OLE Phase) | 0 | |
| Blinded Treatment Phase (100.3 Weeks) | STARTED | Cilofexor From Placebo (OLE Phase) | 0 | |
| Blinded Treatment Phase (100.3 Weeks) | COMPLETED | Cilofexor 100 mg (Blinded Phase) | 123 | |
| Blinded Treatment Phase (100.3 Weeks) | COMPLETED | Placebo (Blinded Phase) | 66 | |
| Blinded Treatment Phase (100.3 Weeks) | COMPLETED | Cilofexor From Cilofexor 100 mg (OLE Phase) | 0 | |
| Blinded Treatment Phase (100.3 Weeks) | COMPLETED | Cilofexor From Placebo (OLE Phase) | 0 | |
| Blinded Treatment Phase (100.3 Weeks) | NOT COMPLETED | Cilofexor 100 mg (Blinded Phase) | 155 | |
| Blinded Treatment Phase (100.3 Weeks) | NOT COMPLETED | Placebo (Blinded Phase) | 75 | |
| Blinded Treatment Phase (100.3 Weeks) | NOT COMPLETED | Cilofexor From Cilofexor 100 mg (OLE Phase) | 0 | |
| Blinded Treatment Phase (100.3 Weeks) | NOT COMPLETED | Cilofexor From Placebo (OLE Phase) | 0 | |
| Open-Label Extension Phase (45 Weeks) | STARTED | Cilofexor 100 mg (Blinded Phase) | 0 | |
| Open-Label Extension Phase (45 Weeks) | STARTED | Placebo (Blinded Phase) | 0 | |
| Open-Label Extension Phase (45 Weeks) | STARTED | Cilofexor From Cilofexor 100 mg (OLE Phase) | 80 | |
| Open-Label Extension Phase (45 Weeks) | STARTED | Cilofexor From Placebo (OLE Phase) | 45 | |
| Open-Label Extension Phase (45 Weeks) | COMPLETED | Cilofexor 100 mg (Blinded Phase) | 0 | |
| Open-Label Extension Phase (45 Weeks) | COMPLETED | Placebo (Blinded Phase) | 0 | |
| Open-Label Extension Phase (45 Weeks) | COMPLETED | Cilofexor From Cilofexor 100 mg (OLE Phase) | 0 | |
| Open-Label Extension Phase (45 Weeks) | COMPLETED | Cilofexor From Placebo (OLE Phase) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03890120/flow